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Abstract
Introduction: Statins reduce coronary events in patients with coronary artery
disease.
Material and methods: Chart reviews were performed in 305 patients (217 men
and 88 women, mean age 74 years) not treated with statins during the first year
of being seen in an outpatient cardiology practice but subsequently treated with
statins. Based on the starting date of statins use, the long-term outcomes of
myocardial infarction (MI), percutaneous coronary intervention (PCI), and coro-
nary artery bypass graft surgery (CABGs) before and after statin use were com-
pared. 
Results: Mean follow-up was 65 months before statins use and 66 months after
statins use. Myocardial infarction occurred in 31 of 305 patients (10%) before
statins, and in 13 of 305 patients (4%) after statins (p < 0.01). Percutaneous
coronary intervention had been performed in 66 of 305 patients (22%) before
statins and was performed in 41 of 305 patients (13%) after statins (p < 0.01).
Coronary artery bypass graft surgery had been performed in 56 of 305 patients
(18%) before statins and in 20 of 305 patients (7%) after statins (p < 0.001).
Stepwise logistic regression showed statins use was an independent risk fac-
tor for MI (odds ratio = 0.0207, 95% CI, 0.0082-0.0522, p < 0.0001), PCI (odds
ratio = 0.0109, 95% CI, 0.0038-0.0315, p < 0.0001) and CABGs (odds ratio =
0.0177, 95% CI = 0.0072-0.0431, p < 0.0001)
Conclusions: Statins use in an outpatient cardiology practice reduces the inci-
dence of MI, PCI, and CABGs. 
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Introduction
Numerous studies have demonstrated that statins reduce the incidence
of coronary events in patients at high risk for coronary events [1-8]. The
efficacy of statins in reducing coronary events in an outpatient cardiolo-
gy practice needed to be investigated. This article reports data compar-
ing the incidence of new myocardial infarction (MI), of new percutaneous
coronary intervention (PCI), and of new coronary artery bypass graft sur-
gery (CABGs) in 305 patients, mean age 74 years (93% with coronary artery
disease), treated in an academic community cardiology practice during the
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time they were not treated with statins vs. during
the time they were subsequently treated with
statins.
Material and methods
Paper and electronics chart reviews were used
to screen patients treated with statins at an aca-
demic community cardiology practice from 1978 to
2008. Based on the starting date of statin use, long-
term clinical outcomes before and after statins start
dates were calculated and compared. Patients who
were treated with statins within the first year of
follow-up were excluded from the study in order to
achieve comparable duration of follow-up. Out of 1,
599 patients screened at the practice [9], 305
patients met all criteria and were included in the
study. 
For every patient, progress notes of all interim vis-
its, letters of correspondence, medication use, blood
pressure, laboratory studies including serum lipid lev-
els, and occurrence of adverse cardiovascular events
from the time of initial presentation to the last fol-
low-up were recorded. Adverse events included
occurrence of MI, need for PCI, and need for CABGs.
Drug therapy and patient comorbidities including
coronary artery disease, hyperlipidemia, hyperten-
sion, diabetes mellitus, cigarette smoking history,
congestive heart failure, angina, atrial fibrillation,
chronic kidney disease, peripheral arterial disease,
abdominal aortic aneurysm, carotid artery stenosis,
transient ischemic attack, stroke, and previous MI,
PCI, and CABGS were recorded. Dates of the events
as well as dates of medication initiation and dis-
continuation were recorded. Coronary artery disease
was diagnosed as previously described [10-16].
Data were extracted by the physician authors
and tabulated with Microsoft Access 2003
(Microsoft Corporation, Redmond, WA, USA). Cus-
tomized computer programming was written for
macros within Microsoft Excel 2003. The McNemar
test was used to compare clinical outcomes.
Adverse events occurring before the time of initial
presentation were not included in the outcomes
analysis. Stepwise logistic regression was performed
with MEDCAL statistical software using the 48 vari-
ables listed in Tables I and II to determine if use of
statins was independently associated with MI, PCI,
and CABGS. A two-sided p value of < 0.05 was con-
sidered significant.
Results
Table I shows the baseline characteristics of the
305 patients. Table II shows the prevalence of use
of drugs in the 305 patients before, after, and
before and after use of statins. Table III shows the
mean blood pressure and serum lipids levels before
and after use of statins. Table III also shows levels
of statistical significance. Table IV shows the inci-
dence of MI, of PCI, and of CABGs before and after
treatment with statins. Table III also shows levels
of statistical significance.
Stepwise logistic regression analysis showed that
use of statins was a significant independent pre-
dictor of new MI (odds ratio = 0.0207; 95% CI
0.0082-0.0522; p < 0.0001), of new PCI (odds ratio
= 0.0109; 95% CI 0.0038-0.0315; p < 0.0001) and of
new CABGs (odds ratio = 0.0177; 95% CI 0.0072-
0.0431; p < 0.0001).
Discussion
Numerous studies have demonstrated that
statins reduce the incidence of coronary events in
patients at high risk for coronary events [1-8]. The
present study compared the incidence of new MI,
of new PCI, and of new CABGs in 305 patients,
mean age 74 years (93% with coronary artery dis-
ease), treated in an academic community cardiolo-
gy practice during the time they were not treated
with statins versus during the time they were sub-
sequently treated with statins.
At 65-month follow-up before treatment with
statins and at 64-month follow-up after treatment
with statins, the incidence of new MI was signifi-
cantly reduced from 10% to 4% by statins (p < 0.01),
Age [years] 74 ±10
Men 217
Women 88
Follow-up before statin use [months] 65
Follow-up after statin use [months] 64
Coronary artery disease 283 (93%)
Hyperlipidemia 270 (89%)
Hypertension 251 (82%)
Diabetes mellitus 76 (25%)
Congestive heart failure 49 (16%)
Angina pectoris 35 (11%)
Atrial fibrillation 54 (18%)
Carotid artery stenosis 18 (6%)
Stroke 30 (10%)
Transient ischemic attack 18 (6%)
Chronic renal disease 8 (3%)
Peripheral arterial disease 35 (11%)
Abdominal aortic aneurysm 12 (4%)
Smoker 130 (43%)
Prior myocardial infarction 102 (33%)
Prior percutaneous coronary intervention 49 (16%)
Prior coronary artery bypass graft surgery 49 (16%)
Table I. Baseline characteristics of 305 patientsArch Med Sci 1, February / 2012 55
The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice
the incidence of new PCI was significantly reduced
from 22% to 13% by statins (p < 0.01), and the inci-
dence of new CABGs was significantly reduced from
18% to 7% by statins (p < 0.001). Stepwise logistic
regression analysis using 48 variables showed that
use of statins was a significant independent risk
factor for reducing new MI, new PCI and new
CABGs (p < 0.0001). 
Our data show that use of statins in patients
with overt coronary artery disease (93%) or at high-
risk for coronary artery disease in a community car-
diology practice can reduce their chance of devel-
oping new MI, new PCI and new CABGs. This study
should give community practitioners, both special-
ists and primary care providers, the encouragement
to pursue cardiovascular risk reduction strategies
as a means for reducing new MI, PCI and CABGs in
their patients. 
A limitation of this study is that it is a retro-
spective chart analysis study with all inherent prob-
lems of such a design.
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